CD73/Adenosine Pathway Involvement in the Interaction of Non-Small Cell Lung Cancer Stem Cells and Bone Cells in the Pre-Metastatic Niche.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
04 May 2022
Historique:
received: 11 04 2022
revised: 01 05 2022
accepted: 03 05 2022
entrez: 14 5 2022
pubmed: 15 5 2022
medline: 18 5 2022
Statut: epublish

Résumé

Adenosinergic signaling is an important regulator of tissue homeostasis and extracellular accumulation of adenosine (Ado) and is associated with different pathologies, such as cancer. In non-small-cell lung cancer (NSCLC), a subset of CD133/CXCR4+ cancer stem cell (CSCs) has been demonstrated to initiate bone metastases. Here we investigated how NSCLC CSCs interact with osteoclasts (OCs) and osteoblasts (OBs) by modulating Ado production and OC activity. We proved that CSC-spheres, generated in vitro from NSCLC cell lines, express CD38, PC-1, and CD73, enzymes of the non-canonical adenosinergic pathway, produce high level of Ado, and down-regulate A1R and A3R inhibitory receptors, while expressing A2AR and A2BR. To address the Ado role and modulation of the in-bone pre-metastatic niche, we performed co-cultures of CSC-spheres with OCs and OBs cells. Firstly, we verified that active OCs do not activate non-canonical the adenosinergic pathway, conversely to OBs. OCs co-cultured with CSC-spheres increase Ado production that is related to the OC resorption activity and contributes to T-cell suppression. Finally, we proved the efficacy of anti-CD73 agents in blocking NSCLC cell migration. Overall, we assessed the importance of adenosinergic signaling in the interaction between CSCs and OCs at the pre-metastatic niche, with therapeutic implications related to Ado production.

Identifiants

pubmed: 35563517
pii: ijms23095126
doi: 10.3390/ijms23095126
pmc: PMC9104817
pii:
doi:

Substances chimiques

Receptor, Adenosine A2A 0
Adenosine K72T3FS567

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : CRT Foundation
ID : CRT2018
Organisme : CRT Foundation
ID : CRT2020
Organisme : Ministero della Salute
ID : RF-2018-12366714
Organisme : Italian Association for Cancer Research
ID : 25023
Organisme : Fondazione Regionale per la Ricerca Biomedica
ID : 1731093
Organisme : Ministero della Salute
ID : ricerca corrente 2021
Organisme : Ministry of Education, Universities and Research
ID : Dipartimenti di Eccellenza ex L.232/2016

Références

Stem Cell Reports. 2018 Apr 10;10(4):1412-1425
pubmed: 29551673
Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16281-6
pubmed: 19805294
Oncogene. 2010 Sep 30;29(39):5346-58
pubmed: 20661219
Expert Rev Mol Med. 2013 Feb 14;15:e1
pubmed: 23406574
FASEB J. 2015 Apr;29(4):1577-90
pubmed: 25573752
Am J Pathol. 2012 Feb;180(2):775-86
pubmed: 22138579
Cancer Cell. 2016 Sep 12;30(3):391-403
pubmed: 27622332
Front Immunol. 2020 Oct 02;11:02168
pubmed: 33123122
J Clin Invest. 2015 Sep;125(9):3384-91
pubmed: 26325035
Trends Endocrinol Metab. 2013 Jun;24(6):290-300
pubmed: 23499155
Physiol Rev. 2018 Jul 1;98(3):1591-1625
pubmed: 29848236
Cancer Discov. 2018 Sep;8(9):1156-1175
pubmed: 30012853
Clin Exp Metastasis. 2007;24(6):439-48
pubmed: 17587186
Pediatr Radiol. 2013 Mar;43(5):589-92
pubmed: 23179487
FEBS Lett. 2011 Jun 6;585(11):1514-20
pubmed: 21514298
Cell. 2008 May 16;133(4):704-15
pubmed: 18485877
J Surg Oncol. 2012 Aug 1;106(2):130-7
pubmed: 22287455
Arthritis Rheum. 2010 Feb;62(2):534-41
pubmed: 20112380
J Immunol. 2013 Oct 15;191(8):4165-73
pubmed: 24043904
Br J Pharmacol. 2013 Jul;169(6):1372-88
pubmed: 23647065
J Bone Miner Res. 2011 Sep;26(9):2112-24
pubmed: 21590734
Clin Exp Rheumatol. 2006 Jul-Aug;24(4):400-6
pubmed: 16956430
JCI Insight. 2022 Feb 8;7(3):
pubmed: 35132961
Blood. 2009 Oct 8;114(15):3216-26
pubmed: 19633200
Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1547-52
pubmed: 20080644
Immunol Lett. 2019 Jan;205:25-30
pubmed: 29550257
Oncoimmunology. 2013 Sep 1;2(9):e26246
pubmed: 24319640
J Biomed Biotechnol. 2012;2012:485156
pubmed: 23125525
J Cancer Res Clin Oncol. 2008 Mar;134(3):365-72
pubmed: 17671792
Eur J Cancer. 2013 Jan;49(2):482-91
pubmed: 22770890
Crit Rev Biochem Mol Biol. 2014 Nov-Dec;49(6):473-97
pubmed: 25418535
Stem Cells Dev. 2013 Apr 1;22(7):1097-111
pubmed: 23259837
Br J Cancer. 2012 Apr 10;106(8):1446-52
pubmed: 22454080
Melanoma Res. 2006 Jun;16(3):213-22
pubmed: 16718268
N Engl J Med. 2012 Dec 13;367(24):2322-33
pubmed: 23234515
FASEB J. 2013 Sep;27(9):3446-54
pubmed: 23682121
Clin Cancer Res. 2016 Jan 1;22(1):158-66
pubmed: 26253870
J Cell Physiol. 2012 Jun;227(6):2622-31
pubmed: 21882189
J Cell Physiol. 2009 Jul;220(1):155-62
pubmed: 19259945
PLoS One. 2010 Aug 27;5(8):e12445
pubmed: 20805998
Purinergic Signal. 2012 Jun;8(2):327-37
pubmed: 22311477
Nat Rev Cancer. 2013 Dec;13(12):842-57
pubmed: 24226193
Cancer Res. 2016 Aug 1;76(15):4372-82
pubmed: 27221704
Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13132-7
pubmed: 16916931
Curr Vasc Pharmacol. 2009 Oct;7(4):426-34
pubmed: 19485885
Bone. 2012 Sep;51(3):389-400
pubmed: 22749889
Cancer Biol Ther. 2013 Sep;14(9):860-8
pubmed: 23917542
Cancer Res. 2011 Apr 15;71(8):2892-900
pubmed: 21292811
Front Immunol. 2019 Jun 06;10:925
pubmed: 31244820
Nat Commun. 2016 Feb 17;7:10501
pubmed: 26883990
World J Gastroenterol. 2013 Mar 28;19(12):1912-8
pubmed: 23569336
Cancer Res. 2010 Mar 15;70(6):2245-55
pubmed: 20179192
Mol Cancer Ther. 2020 Nov;19(11):2340-2352
pubmed: 32943546
Cancer Res. 2015 Sep 1;75(17):3636-49
pubmed: 26141860
Oncol Lett. 2015 Jun;9(6):2485-2494
pubmed: 26137095
Biochim Biophys Acta. 2014 Dec;1843(12):2957-66
pubmed: 25241343
FASEB J. 2011 Apr;25(4):1264-74
pubmed: 21233486
J Bone Miner Res. 2006 Feb;21(2):228-36
pubmed: 16418778
Cells. 2015 Sep 17;4(3):520-37
pubmed: 26393653
J Clin Oncol. 2019 Feb 1;37(4):269-277
pubmed: 30523712
J Cell Physiol. 2011 May;226(5):1353-66
pubmed: 20945394
Oncoimmunology. 2017 Apr 21;6(6):e1320011
pubmed: 28680754
Biomed Res Int. 2020 Dec 3;2020:5197626
pubmed: 33344638
Immunol Rev. 2017 Mar;276(1):121-144
pubmed: 28258700
Oncotarget. 2017 Jan 31;8(5):8738-8751
pubmed: 28060732

Auteurs

Giulia Bertolini (G)

Tumor Genomics Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.

Mara Compagno (M)

Center for Research and Medical Studies (CeRMS), A.O.U. Città della Salute e della Scienza di Torino, 10126 Turin, Italy.

Dimas Carolina Belisario (DC)

Center for Research and Medical Studies (CeRMS), A.O.U. Città della Salute e della Scienza di Torino, 10126 Turin, Italy.

Cristiano Bracci (C)

Laboratory of Immunogenetics, Department of Medical Sciences, University of Turin, 10126 Turin, Italy.

Tullio Genova (T)

Department of Life Sciences and Systems Biology, University of Turin, 10123 Turin, Italy.

Federico Mussano (F)

C.I.R Dental School, Department of Surgical Sciences, Bone and Dental Bioengineering Laboratory, University of Turin, 10126 Turin, Italy.

Massimo Vitale (M)

IRCCS Ospedale Policlinico San Martino Genova, UOC Immunologia, 16132 Genoa, Italy.

Alberto Horenstein (A)

Laboratory of Immunogenetics, Department of Medical Sciences, University of Turin, 10126 Turin, Italy.

Fabio Malavasi (F)

Department of Medical Sciences, University of Turin, 10124 Turin, Italy.

Riccardo Ferracini (R)

C.I.R Dental School, Department of Surgical Sciences, Bone and Dental Bioengineering Laboratory, University of Turin, 10126 Turin, Italy.
Department of Surgical Sciences (DISC), University of Genoa, 16132 Genoa, Italy.

Ilaria Roato (I)

C.I.R Dental School, Department of Surgical Sciences, Bone and Dental Bioengineering Laboratory, University of Turin, 10126 Turin, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH